{"id":6748,"date":"2026-07-01T00:02:43","date_gmt":"2026-06-30T23:02:43","guid":{"rendered":"https:\/\/lenus-healthcare.com\/?p=6748"},"modified":"2026-06-15T14:40:48","modified_gmt":"2026-06-15T13:40:48","slug":"yuviwel-fda-approval-achondroplasia","status":"publish","type":"post","link":"https:\/\/lenus-healthcare.com\/en\/yuviwel-fda-approval-achondroplasia\/","title":{"rendered":"FDA Approves Yuviwel for Pediatric Patients With Achondroplasia"},"content":{"rendered":"<p>Achondroplasia is the most common form of dwarfism and is characterized by impaired bone growth leading to short stature and disproportionate skeletal development. The condition is caused by a genetic mutation affecting bone growth regulation and may significantly impact physical development and quality of life in affected children.<\/p>\n<p>At Lenus Health, we continuously follow global pharmaceutical and regulatory developments to provide valuable healthcare insights and support informed industry collaboration.<\/p>\n<p>According to the <a href=\"https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-drug-pediatric-patients-most-common-form-dwarfism?utm_source=chatgpt.com\">official FDA announcement<\/a>, the U.S. Food and Drug Administration approved Yuviwel (navepegritide) injection to improve growth in pediatric patients aged two years and older with achondroplasia and open epiphyses (growth plates).<\/p>\n<blockquote><p><a href=\"https:\/\/lenus-healthcare.com\/en\/contact-us\/#form-contact\"><strong>For international supply and commercial inquiries regarding this product, please contact the Lenus Health sales team.<\/strong><\/a><\/p><\/blockquote>\n<p><strong>Table of Contents<\/strong><\/p>\n<ul>\n<li><a href=\"#Introduction\">Introduction to Yuviwel and Mechanism of Action<\/a><\/li>\n<li><a href=\"#Understanding\">Understanding Achondroplasia<\/a><\/li>\n<li><a href=\"#Clinical\">Clinical Trial Findings<\/a><\/li>\n<li><a href=\"#Growth\">Growth Outcomes and Efficacy Data<\/a><\/li>\n<li><a href=\"#Safety\">Safety Information and Adverse Events<\/a><\/li>\n<li><a href=\"#FDA\">FDA Accelerated Approval and Priority Review<\/a><\/li>\n<li><a href=\"#Conclusion\">Conclusion and Future Perspectives<\/a><\/li>\n<li><a href=\"#faq\">Frequently Asked Questions (FAQs)<\/a><\/li>\n<\/ul>\n<h2 id=\"Introduction\">1. Introduction to Yuviwel and Mechanism of Action<\/h2>\n<p>Yuviwel (navepegritide) is an injectable therapy developed to improve growth in children with achondroplasia.<\/p>\n<p>Achondroplasia is associated with excessive activity of fibroblast growth factor receptor 3 (FGFR3), a protein that negatively regulates bone growth. By targeting pathways involved in skeletal development, Yuviwel aims to improve longitudinal bone growth and increase annualized growth velocity (AGV).<\/p>\n<p>The therapy is administered:<\/p>\n<ul>\n<li>As a once-weekly subcutaneous injection<\/li>\n<\/ul>\n<h2 id=\"Understanding\">2. Understanding Achondroplasia<\/h2>\n<p>Achondroplasia is a genetic disorder causing disproportionate short stature.<\/p>\n<p>The condition occurs due to mutations affecting FGFR3 activity, which inhibits normal bone development.<\/p>\n<p>Common characteristics include:<\/p>\n<ul>\n<li>Short stature<\/li>\n<li>Shortened limbs<\/li>\n<li>Disproportionate skeletal growth<\/li>\n<li>Delayed bone development<\/li>\n<\/ul>\n<p>The condition affects approximately:<\/p>\n<ul>\n<li>1 in 10,000 to 1 in 30,000 live births annually<\/li>\n<\/ul>\n<p>The average adult height in individuals with achondroplasia is approximately four feet.<\/p>\n<p><img decoding=\"async\" src=\"\/wp-content\/uploads\/2026\/07\/Yuviwel-FDA-Zulassung-Achondroplasie01.jpg\" alt=\"Understanding Achondroplasia\" width=\"100%\" height=\"auto\" \/><\/p>\n<h2 id=\"Clinical\">3. Clinical Trial Findings<\/h2>\n<p>The effectiveness of Yuviwel was evaluated in:<\/p>\n<ul>\n<li>Trial 1 (NCT05598320)<\/li>\n<li>Randomized, placebo-controlled, double-blind study<\/li>\n<li>52-week treatment period<\/li>\n<li>Followed by a 52-week open-label extension<\/li>\n<\/ul>\n<p><strong>Study Population<\/strong><\/p>\n<p>The study included:<\/p>\n<ul>\n<li>84 pediatric patients with genetically confirmed achondroplasia<\/li>\n<li>No prior treatment history<\/li>\n<\/ul>\n<p>Treatment groups:<\/p>\n<ul>\n<li>57 patients received Yuviwel 0.1 mg\/kg once weekly<\/li>\n<li>27 patients received placebo<\/li>\n<\/ul>\n<h2 id=\"Growth\">4. Growth Outcomes and Efficacy Data<\/h2>\n<p><strong>Primary Efficacy Endpoint<\/strong><\/p>\n<p>The primary endpoint was:<\/p>\n<ul>\n<li>Annualized growth velocity (AGV) at Week 52<\/li>\n<\/ul>\n<p><strong>Results<\/strong><\/p>\n<p>Patients treated with Yuviwel achieved:<\/p>\n<ul>\n<li>An average increase of 1.5 cm in height growth compared with placebo over 52 weeks<\/li>\n<\/ul>\n<p>During the open-label extension:<\/p>\n<ul>\n<li>Patients receiving two years of therapy maintained growth velocity during the second year of treatment<\/li>\n<\/ul>\n<p>These findings supported accelerated FDA approval based on improvement in growth rate.<\/p>\n<h2 id=\"Safety\">5. Safety Information and Adverse Events<\/h2>\n<p><strong>Important Safety Considerations<\/strong><\/p>\n<p>Transient low blood pressure has been reported with this class of medications.<\/p>\n<p>Patients should seek medical attention if they experience:<\/p>\n<ul>\n<li>Dizziness<\/li>\n<li>Lightheadedness<\/li>\n<li>Fainting<\/li>\n<li>Blurred vision<\/li>\n<\/ul>\n<p>during treatment.<\/p>\n<p><strong>Most Common Side Effects<\/strong><\/p>\n<p>The most frequently reported adverse events include:<\/p>\n<ul>\n<li>Vomiting<\/li>\n<li>Injection-site reactions<\/li>\n<li>Pain in extremities<\/li>\n<li>Nausea<\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"\/wp-content\/uploads\/2026\/07\/Yuviwel-FDA-Zulassung-Achondroplasie00.jpg\" alt=\"Patients under Yuviwel\" width=\"100%\" height=\"auto\" \/><\/p>\n<h2 id=\"FDA\">6. FDA Accelerated Approval and Priority Review<\/h2>\n<p>Yuviwel received:<\/p>\n<ul>\n<li>Priority Review designation<\/li>\n<li>Accelerated Approval<\/li>\n<\/ul>\n<p>The accelerated approval pathway was based on improvement in annualized growth velocity.<\/p>\n<p>As part of the approval conditions:<\/p>\n<ul>\n<li>An ongoing study is required to confirm improvement in final adult height.<\/li>\n<\/ul>\n<h2 id=\"Conclusion\">7. Conclusion and Future Perspectives<\/h2>\n<p>The FDA approval of Yuviwel (navepegritide) represents an important advancement in the treatment of pediatric achondroplasia, the most common form of dwarfism.<\/p>\n<p>Clinically, the observed improvement in annualized growth velocity suggests that targeting growth regulation pathways may offer meaningful benefits for affected children during critical developmental stages.<\/p>\n<p>The approval also highlights the growing focus on therapies designed to address the underlying biological mechanisms of rare genetic disorders rather than solely managing symptoms.<\/p>\n<p>However, long-term follow-up studies will remain essential to determine whether improvements in growth velocity ultimately translate into increased adult height and broader functional outcomes.<\/p>\n<p>Future real-world data and extended clinical observations will further clarify the long-term safety profile and therapeutic role of Yuviwel in pediatric growth disorders.<\/p>\n<p>Lenus Health continues to monitor emerging therapies and pharmaceutical innovations shaping the future of healthcare.<\/p>\n<blockquote><p><a href=\"https:\/\/lenus-healthcare.com\/en\/contact-us\/#form-contact\"><strong>For international supply and commercial inquiries regarding this product, please contact the Lenus Health sales team.<\/strong><\/a><\/p><\/blockquote>\n<h2 id=\"faq\">8. Frequently Asked Questions (FAQs)<\/h2>\n<ul>\n<li><strong>What is Yuviwel used for?<br \/>\n<\/strong>Yuviwel is approved to improve growth in pediatric patients aged two years and older with achondroplasia.<\/li>\n<li><strong>What is achondroplasia?<br \/>\n<\/strong>Achondroplasia is the most common form of dwarfism caused by a genetic mutation affecting bone growth.<\/li>\n<li><strong>How is Yuviwel administered?<br \/>\n<\/strong>It is administered as a once-weekly subcutaneous injection.<\/li>\n<li><strong>What was the main clinical benefit observed?<br \/>\n<\/strong>Patients treated with Yuviwel showed improved annualized growth velocity and increased height growth compared with placebo.<br \/>\n<strong>What are the most common side effects?<\/strong><\/li>\n<li>Vomiting, injection-site reactions, limb pain, and nausea.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Pediatric Growth Therapy<\/p>\n","protected":false},"author":2,"featured_media":6744,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_joinchat":[],"footnotes":""},"categories":[120],"tags":[],"class_list":["post-6748","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-new-medicine"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Yuviwel FDA Approval Achondroplasia | Pediatric Growth Therapy<\/title>\n<meta name=\"description\" content=\"Yuviwel FDA approval achondroplasia | FDA approves Yuviwel for children with the most common form of dwarfism.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lenus-healthcare.com\/yuviwel-fda-zulassung-achondroplasie\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Yuviwel FDA Approval Achondroplasia | Pediatric Growth Therapy\" \/>\n<meta property=\"og:description\" content=\"Yuviwel FDA approval achondroplasia | FDA approves Yuviwel for children with the most common form of dwarfism.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lenus-healthcare.com\/yuviwel-fda-zulassung-achondroplasie\/\" \/>\n<meta property=\"og:site_name\" content=\"Lenus Health\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-30T23:02:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2026\/07\/Yuviwel-FDA-Zulassung-AchondroplasieTH.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"873\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"login-hashemzadeh-dash\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"login-hashemzadeh-dash\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/yuviwel-fda-zulassung-achondroplasie\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/yuviwel-fda-zulassung-achondroplasie\\\/\"},\"author\":{\"name\":\"login-hashemzadeh-dash\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/#\\\/schema\\\/person\\\/0abed38587372602833862aaf8e51e09\"},\"headline\":\"FDA Approves Yuviwel for Pediatric Patients With Achondroplasia\",\"datePublished\":\"2026-06-30T23:02:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/yuviwel-fda-zulassung-achondroplasie\\\/\"},\"wordCount\":759,\"publisher\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/yuviwel-fda-zulassung-achondroplasie\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lenus-healthcare.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Yuviwel-FDA-Zulassung-AchondroplasieTH.jpg\",\"articleSection\":[\"New medicines\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/yuviwel-fda-zulassung-achondroplasie\\\/\",\"url\":\"https:\\\/\\\/lenus-healthcare.com\\\/yuviwel-fda-zulassung-achondroplasie\\\/\",\"name\":\"Yuviwel FDA Approval Achondroplasia | Pediatric Growth Therapy\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/yuviwel-fda-zulassung-achondroplasie\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/yuviwel-fda-zulassung-achondroplasie\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lenus-healthcare.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Yuviwel-FDA-Zulassung-AchondroplasieTH.jpg\",\"datePublished\":\"2026-06-30T23:02:43+00:00\",\"description\":\"Yuviwel FDA approval achondroplasia | FDA approves Yuviwel for children with the most common form of dwarfism.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/yuviwel-fda-zulassung-achondroplasie\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/lenus-healthcare.com\\\/yuviwel-fda-zulassung-achondroplasie\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/yuviwel-fda-zulassung-achondroplasie\\\/#primaryimage\",\"url\":\"https:\\\/\\\/lenus-healthcare.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Yuviwel-FDA-Zulassung-AchondroplasieTH.jpg\",\"contentUrl\":\"https:\\\/\\\/lenus-healthcare.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Yuviwel-FDA-Zulassung-AchondroplasieTH.jpg\",\"width\":1600,\"height\":873,\"caption\":\"Pediatric Growth Therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/yuviwel-fda-zulassung-achondroplasie\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neue Medikamente\",\"item\":\"https:\\\/\\\/lenus-healthcare.com\\\/category\\\/neue-medikamente\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"FDA Approves Yuviwel for Pediatric Patients With Achondroplasia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/#website\",\"url\":\"https:\\\/\\\/lenus-healthcare.com\\\/\",\"name\":\"Lenus Health\",\"description\":\"Lenus Health Gmbh | Berlin\",\"publisher\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/lenus-healthcare.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/#organization\",\"name\":\"Lenus Health\",\"url\":\"https:\\\/\\\/lenus-healthcare.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/lenus-healthcare.com\\\/wp-content\\\/uploads\\\/2017\\\/07\\\/Logo-pur.webp\",\"contentUrl\":\"https:\\\/\\\/lenus-healthcare.com\\\/wp-content\\\/uploads\\\/2017\\\/07\\\/Logo-pur.webp\",\"width\":1275,\"height\":298,\"caption\":\"Lenus Health\"},\"image\":{\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/lenus-healthcare.com\\\/#\\\/schema\\\/person\\\/0abed38587372602833862aaf8e51e09\",\"name\":\"login-hashemzadeh-dash\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b58400e93864034c4119dff6d018160c0ebf646c52f088b18a3bde50dc9174f6?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b58400e93864034c4119dff6d018160c0ebf646c52f088b18a3bde50dc9174f6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b58400e93864034c4119dff6d018160c0ebf646c52f088b18a3bde50dc9174f6?s=96&d=mm&r=g\",\"caption\":\"login-hashemzadeh-dash\"},\"url\":\"https:\\\/\\\/lenus-healthcare.com\\\/en\\\/author\\\/login-hashemzadeh-dash\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Yuviwel FDA Approval Achondroplasia | Pediatric Growth Therapy","description":"Yuviwel FDA approval achondroplasia | FDA approves Yuviwel for children with the most common form of dwarfism.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lenus-healthcare.com\/yuviwel-fda-zulassung-achondroplasie\/","og_locale":"en_US","og_type":"article","og_title":"Yuviwel FDA Approval Achondroplasia | Pediatric Growth Therapy","og_description":"Yuviwel FDA approval achondroplasia | FDA approves Yuviwel for children with the most common form of dwarfism.","og_url":"https:\/\/lenus-healthcare.com\/yuviwel-fda-zulassung-achondroplasie\/","og_site_name":"Lenus Health","article_published_time":"2026-06-30T23:02:43+00:00","og_image":[{"width":1600,"height":873,"url":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2026\/07\/Yuviwel-FDA-Zulassung-AchondroplasieTH.jpg","type":"image\/jpeg"}],"author":"login-hashemzadeh-dash","twitter_card":"summary_large_image","twitter_misc":{"Written by":"login-hashemzadeh-dash","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lenus-healthcare.com\/yuviwel-fda-zulassung-achondroplasie\/#article","isPartOf":{"@id":"https:\/\/lenus-healthcare.com\/yuviwel-fda-zulassung-achondroplasie\/"},"author":{"name":"login-hashemzadeh-dash","@id":"https:\/\/lenus-healthcare.com\/#\/schema\/person\/0abed38587372602833862aaf8e51e09"},"headline":"FDA Approves Yuviwel for Pediatric Patients With Achondroplasia","datePublished":"2026-06-30T23:02:43+00:00","mainEntityOfPage":{"@id":"https:\/\/lenus-healthcare.com\/yuviwel-fda-zulassung-achondroplasie\/"},"wordCount":759,"publisher":{"@id":"https:\/\/lenus-healthcare.com\/#organization"},"image":{"@id":"https:\/\/lenus-healthcare.com\/yuviwel-fda-zulassung-achondroplasie\/#primaryimage"},"thumbnailUrl":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2026\/07\/Yuviwel-FDA-Zulassung-AchondroplasieTH.jpg","articleSection":["New medicines"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/lenus-healthcare.com\/yuviwel-fda-zulassung-achondroplasie\/","url":"https:\/\/lenus-healthcare.com\/yuviwel-fda-zulassung-achondroplasie\/","name":"Yuviwel FDA Approval Achondroplasia | Pediatric Growth Therapy","isPartOf":{"@id":"https:\/\/lenus-healthcare.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lenus-healthcare.com\/yuviwel-fda-zulassung-achondroplasie\/#primaryimage"},"image":{"@id":"https:\/\/lenus-healthcare.com\/yuviwel-fda-zulassung-achondroplasie\/#primaryimage"},"thumbnailUrl":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2026\/07\/Yuviwel-FDA-Zulassung-AchondroplasieTH.jpg","datePublished":"2026-06-30T23:02:43+00:00","description":"Yuviwel FDA approval achondroplasia | FDA approves Yuviwel for children with the most common form of dwarfism.","breadcrumb":{"@id":"https:\/\/lenus-healthcare.com\/yuviwel-fda-zulassung-achondroplasie\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lenus-healthcare.com\/yuviwel-fda-zulassung-achondroplasie\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lenus-healthcare.com\/yuviwel-fda-zulassung-achondroplasie\/#primaryimage","url":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2026\/07\/Yuviwel-FDA-Zulassung-AchondroplasieTH.jpg","contentUrl":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2026\/07\/Yuviwel-FDA-Zulassung-AchondroplasieTH.jpg","width":1600,"height":873,"caption":"Pediatric Growth Therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/lenus-healthcare.com\/yuviwel-fda-zulassung-achondroplasie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/lenus-healthcare.com\/en\/"},{"@type":"ListItem","position":2,"name":"Neue Medikamente","item":"https:\/\/lenus-healthcare.com\/category\/neue-medikamente\/"},{"@type":"ListItem","position":3,"name":"FDA Approves Yuviwel for Pediatric Patients With Achondroplasia"}]},{"@type":"WebSite","@id":"https:\/\/lenus-healthcare.com\/#website","url":"https:\/\/lenus-healthcare.com\/","name":"Lenus Health","description":"Lenus Health Gmbh | Berlin","publisher":{"@id":"https:\/\/lenus-healthcare.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lenus-healthcare.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/lenus-healthcare.com\/#organization","name":"Lenus Health","url":"https:\/\/lenus-healthcare.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lenus-healthcare.com\/#\/schema\/logo\/image\/","url":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2017\/07\/Logo-pur.webp","contentUrl":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2017\/07\/Logo-pur.webp","width":1275,"height":298,"caption":"Lenus Health"},"image":{"@id":"https:\/\/lenus-healthcare.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/lenus-healthcare.com\/#\/schema\/person\/0abed38587372602833862aaf8e51e09","name":"login-hashemzadeh-dash","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b58400e93864034c4119dff6d018160c0ebf646c52f088b18a3bde50dc9174f6?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b58400e93864034c4119dff6d018160c0ebf646c52f088b18a3bde50dc9174f6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b58400e93864034c4119dff6d018160c0ebf646c52f088b18a3bde50dc9174f6?s=96&d=mm&r=g","caption":"login-hashemzadeh-dash"},"url":"https:\/\/lenus-healthcare.com\/en\/author\/login-hashemzadeh-dash\/"}]}},"_links":{"self":[{"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/posts\/6748","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/comments?post=6748"}],"version-history":[{"count":5,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/posts\/6748\/revisions"}],"predecessor-version":[{"id":6753,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/posts\/6748\/revisions\/6753"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/media\/6744"}],"wp:attachment":[{"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/media?parent=6748"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/categories?post=6748"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/tags?post=6748"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}